Celldex Announces Upcoming Presentation of CDX-0159 Phase 1b Results in Inducible Urticaria at the 2021 European Academy of Dermatology and Venereology (EADV) 30th Congress
Celldex Therapeutics (NASDAQ:CLDX) announced that an abstract on CDX-0159's efficacy in managing symptoms of cold contact urticaria and symptomatic dermographism will be presented at the European Academy of Dermatology and Venereology 30th Congress from September 29 to October 2, 2021. The presentation highlights the antibody's rapid clinical response and quality of life improvements. Interim data available at submission in May will be updated at the event. CDX-0159 targets the KIT receptor, essential for mast cell function in chronic urticaria.
- CDX-0159 shows rapid and sustained clinical response.
- The study highlights significant improvements in patients' quality of life.
- Presentation at a prominent dermatology congress increases visibility and potential market interest.
- Interim data may suggest the need for further validation before commercializing CDX-0159.
- Dependence on future clinical trial results could introduce uncertainties.
HAMPTON, N.J., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing symptom control and quality of life measurements from the Phase 1b study of CDX-0159 in patients with antihistamine refractory cold contact urticaria (ColdU) and symptomatic dermographism (SD), the two most common forms of chronic inducible urticaria (CIndU), has been accepted as an electronic poster (with voice over) at the European Academy of Dermatology and Venereology (EADV) 30th Congress being held virtually September 29 - October 2, 2021.
Presentation details:
| Presentation #P0368: | CDX-0159, an anti-KIT antibody, demonstrates rapid and sustained clinical response and improved quality of life in patients with chronic inducible urticaria |
| Date: | Pre-recorded poster discussion available on demand from Wednesday, September 29 at 6:00 a.m. CET (Wednesday, September 29 at 12:00 a.m. EDT) |
| Session type: | Electronic poster |
| Session Category: | Biologics, immunotherapy, targeted therapy |
Interim data included in the abstract were current as of the time of submission in May; updated results will be presented at EADV.
About CDX-0159
CDX-0159 is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. In certain inflammatory diseases, such as chronic urticaria, mast cell activation plays a central role in the onset and progression of the disease.
About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com.
Forward Looking Statement
This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates, including CDX-0159, in current or future indications; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the effects of the outbreak of COVID-19 on our business and results of operations; the availability, cost, delivery and quality of clinical materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; and other factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com
Patrick Till
Senior Director, Investor Relations & Corporate Communications
(484) 788-8560
ptill@celldex.com
FAQ
What are the results of the CDX-0159 Phase 1b study?
When will the CDX-0159 results be presented?
What is CDX-0159 used for?
What are the implications of the EADV presentation for CLDX stock?
